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CLINICAL SCIENCE
Interruption of Highly Active Antiretroviral Therapy
in HIV Clinical Practice
Results From the Italian Cohort of Antiretroviral-Naive Patients
Antonella d’Arminio Monforte, MD,* Alessandro Cozzi-Lepri, PhD,† Andrew Phillips, PhD,†
Andrea De Luca, MD,‡ Rita Murri, MD,‡ Cristina Mussini, MD,§ Paolo Grossi, MD,k
Andrea Galli, MD,¶ Tiziano Zauli, MD,# Maria Montroni, MD,** Paolo Tundo, MD,††
and Mauro Moroni, MD* for the Italian Cohort of Antiretroviral-Naive Patients Study Group
Objectives: To investigate the frequency of a first therapy
interruption (TI) $12 weeks, to identify the factors associated with
TI and with therapy resumption, and to compare the risk of devel-
oping clinical events during TI and during continuous therapy.
Methods: Observational study of 3142 patients who started a first
highly active antiretroviral therapy (HAART) regimen. End points
were time to (1) first TI of $12 weeks, (2) subsequent therapy
resumption, and (3) development of new AIDS-related events or
death.
Results: Over a median follow-up period of 41 months (interquartile
range: 18–60 months), 721 patients (22.9%) interrupted HAART for
$12 weeks, with a probability of 28.6% (95% confidence interval
[CI]: 26.7–30.6) by 4 years from the date of therapy initiation. Patient
decision (47.4%) and toxicity (24.0%) were the main reasons for TI.
Women, injection drug users, and patients with a higher current CD4
cell count were more likely to interrupt. The median time to therapy
resumption was 12 months (95% CI: 11–14). The higher the current
CD4 count, the slower was the rate of resuming therapy; conversely,
patients who stopped because of failure and those with a pre-HAART
viral load .100,000 copies/mL resumed therapy sooner. Two
hundred eighty-one patients experienced clinical progression at a rate
of 2.6 per 100 person-years (pys) (95% CI: 2.3–3.0) while patients
were on therapy and 3.5 per 100 pys (95% CI: 2.4–4.8) during TI. The
adjusted relative hazard of clinical progression associated with TI was
2.75 (95% CI: 1.14–6.65; P = 0.03).
Conclusions: TI occurring in clinical practice is associated with an
increased risk of clinical progression; hence, it should be discouraged
outside strictly experimental settings.
Key Words: highly active antiretroviral therapy, treatment inter-
ruption, clinical setting, clinical progression
(J Acquir Immune Defic Syndr 2005;38:407–416)
The efficacy of highly active antiretroviral therapy(HAART) has been well demonstrated by trends in mor-
bidity and mortality over calendar time,1,2 in randomized cli-
nical trials,3,4 and in cohort studies studying subjects starting
such regimens.5,6 Nevertheless, the complexity of the regim-
ens, the frequent occurrence of adverse events, and incomplete
adherence leading to the emergence of resistant viruses7,8 have
resulted in investigation of alternatives to continuous lifelong
therapy. Structured treatment interruption (STI) strategies have
been investigated in subjects with well-controlled viral
replication and in subjects with multiple failures. Although
the rationale for the use of STI in these 2 clinical situations is
different, being to reduce the total exposure to therapy and/or
to enhance HIV-specific cellular immune response in the first
case and to re-establish the circulation in plasma of a virus that
is sensitive to antiretroviral drugs in the second case, preli-
minary results on the safety and benefit of such approaches are
mixed.9–15 Similarly, cohort studies examining unsupervised
therapy interruptions have not so far provided a consistent
guide to the risks, in terms of CD4 cell count depletion and
occurrence of AIDS-related diseases.16–21 Therefore, STI str-
ategies are still considered to be experimental and limited to
patients included in clinical research studies.22 Nevertheless,
a considerable proportion of patients in the clinical setting
choose to temporarily discontinue therapy, often without
supervision by their treating clinician, because of toxicity or
because of the desire to have a break from therapy.
The aim of this study was to investigate the frequency of
treatment interruption (TI) in a large cohort of patients after
they underwent their first HAART regimen so as to identify the
factors associated with the occurrence of their first TI as well
as those associated with subsequent therapy resumption and to
investigate whether there is an increased risk of developing
clinical events during TI compared with periods of continuous
therapy.
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METHODS
The Italian Cohort of Antiretroviral-Naive Patients
(I.Co.N.A.) is a cohort that was set up in 1997, and it in-
cludes patients consecutively enrolled from 69 departments of
infectious diseases all over Italy. To be recruited, patients have
to be naive to antiretroviral treatment, irrespective of the rea-
son for being so; they all signed consent forms to participate in
the cohort study. Details of the I.Co.N.A. study are given
elsewhere.7 Briefly, in the I.Co.N.A. database, the reasons for
switching or interrupting therapy (as given by clinicians) were
coded as: patient decision, side effects/toxicity, therapy failure,
and other reasons (eg, therapy contraindications, adherence,
simplification). I.Co.N.A. clinicians typically tick the box
‘‘patient decision’’ when the decision to interrupt therapy is
primarily made by the patient, who informs his or her treating
doctor at the next visit.
Patients were included in the present analysis if they had
started a first HAART regimen (defined as a regimen con-
taining at least 3 drugs chosen from among nucleoside reverse
transcriptase inhibitors [NRTIs], protease inhibitors [PIs], and
nonnucleoside reverse transcriptase inhibitors [NNRTIs]) and
had at least 1 clinical follow-up visit after HAART initiation.
When more than 1 drug was interrupted at the same time
and the reason given was different according to the drug
stopped, the reason given for stopping the ‘‘third’’ drug
(typically, the PI or NNRTI) was used in the analysis.
Three main end points were considered in this analysis.
The first end point was the time from HAART initiation to the
first time at which all the drugs were interrupted for a period of
at least 12 weeks (ie, patients who interrupted HAART but
restarted therapy within 12 weeks were not defined as having
a TI). Similarly, the follow-up of patients who had their last
clinical visit less than 12 weeks after the date of TI were
censored at this date, and the TI was ignored. A complete
interruption longer than 12 weeks occurring after 1 or more of
these shorter interruptions was a defining event, however.
Indeed, we thought that interruptions shorter than 12 weeks
should not be considered as real preplanned interruptions.
The second end point was therapy resumption, defined
as the time from therapy interruption to the time of restarting 1
or more antiretrovirals. Follow-up of patients for whom ther-
apy was not resumed was censored at the date of the last cli-
nical follow-up visit.
Standard survival analysis methods, including Kaplan-
Meier estimation and Cox proportional hazards models, were
used to analyze the rate and determinants of the first TI and of
therapy resumption after the first TI. To calculate the proba-
bility of the first TI according to the duration of time since
HAART initiation, the arbitrary date (before enrollment) of
January 1, 1996 was chosen as time 0 for the analysis. This
time was chosen rather than the date of initiation of HAART;
otherwise, the covariate ‘‘cumulative time spent on HAART’’
and the survival time would be identical, and it would not be
possible to obtain a useful estimate of the relative hazard (RH)
associated with this factor from fitting a Cox model.
For the subgroup of patients who interrupted therapy at
a CD4 cell count greater than 200 cells/mL, we estimated the
probability of resuming therapy by the time of reaching a CD4
count less than 200 cells/mL. The structure of repeated CD4
count data is comparable with that of censored time-to-event
data such that it was possible to define a ‘‘censored’’ minimum
CD4 count observed over follow-up for patients who did not
restart therapy and a ‘‘known’’ minimum CD4 count for those
who restarted, which was defined as failure; the Kaplan-Meier
method can then be used to estimate the CD4 count at which
a certain proportion of the patients would be expected to restart
therapy. The SAS statistical package was used after subtracting
to the minimum CD4 count, calculated separately for each
patient, a constant such that all observations were positive (as
required by the package). Details of this method are described
elsewhere.23 Survival times were left truncated at the CD4
count at the time of the first TI such that patients were
considered to be ‘‘at risk’’ only starting from their own CD4
count measured at the time of TI.
The third end point was the development of a new
AIDS-defining event or death. AIDS-defining events were
classified according to the 1993 Centers for Disease Control
and Prevention (CDC) guidelines.24 Only the first clinical
event since the initiation of HAART was accounted for; time
0 was the time of initiation of first HAART, and follow-up of
patients who did not develop an event was censored at the date
of the last clinical follow-up. For this end point, all the TIs
longer than 12 weeks experienced during the follow-up period
(and not just the first TI) were taken into account. The number
of new clinical events and the follow-up time that patients
spent on therapy and off therapy were calculated. The rate of
clinical events was expressed per person-year (py) of follow-
up, and the rate ratios (RRs) with 95% confidence intervals
(CIs; rate off therapy vs. rate on therapy) were determined,
using univariate Poisson regression, overall and stratified by
the current CD4 cell count. The risk of clinical progression
associated with TI was also assessed in a multivariate pro-
portional hazards model, including a time-dependent covariate
taking the value of 0 if a patient was on therapy or during the
first 12 weeks of TI and taking the value of 1 from the point
in time at which a patient had been off therapy for $12 weeks
up to the date that he or she restarted therapy or the date of
the last clinical visit, whichever occurred first. The 12-week
lag was introduced to try to minimize the potential reverse
causality problem resulting from the fact that patients some-
times discontinue their treatment as a consequence of immi-
nent death.
The covariates for the current time-dependent absolute
levels of CD4 cell count, viral load, and triglycerides (and
marker changes from pretherapy levels) were constructed
using all the measurements available without any time restric-
tion on how recent a measurement had to be.
RESULTS
Study Population
A total of 3142 patients were included in the analysis.
Overall, the median CD4 count before starting HAART was
284 cells/mL (interquartile range [IQR]:127–450 cells/mL),
and the viral load was 4.70 log10 copies/mL (IQR: 3.97–5.23
log10 copies/mL). The median calendar year of starting
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HAARTwas 1999 (range: 1997–2004). The remaining general
characteristics of the patients according to the number and
duration of TIs (none or,12 weeks, 1 TI$12 weeks, or more
than 1 TI $12 weeks) are shown in Table 1.
Over a median clinical follow-up of 41 months (IQR:
18–60 months), a total of 721 patients (22.9%) interrupted
HAART for at least 12 weeks: 655 (20.8%) had a single
interruption, 54 (1.7%) had 2 interruptions, and 12 (0.4%) had
3 interruptions for a total of 1015 interruptions. The first of
these interruptions occurred in the calendar period ranging
between September 1997 and February 2004. The median
CD4 count and viral load at time of the first HAART
interruption were 532 cells/mL (IQR: 307–784 cells/mL) and
2.71 log10 copies/mL (IQR: 1.90–4.29 log10 copies/mL),
respectively; at the time of interruption, 50.5% of patients (n =
364) had a viral load.500 copies/mL, whereas in 357 patients
(49.5%), the viral load was undetectable (n = 186 at a cutoff of
500 copies/mL and n = 171 at a cutoff of 50 copies/mL). The
most common type of regimen that patients had been receiving
when the interruption took place was a combination of 2
NRTIs and a single PI (46.3%), followed by 2 NRTIs and an
NNRTI (34.8%); 3 NRTIs, with 1 being abacavir (7.6%); and
ritonavir-boosted PI combinations (3.3%). The most frequent
reason for interruption was patient decision (47.4% [n = 342]),
followed by toxicity (24.0% [n = 173]), other reasons (24.1%
[clinical contraindications, n = 23; poor adherence, n = 41; and
clinical decision, n = 9]), and therapy failure (4.4% [n = 32]).
The reason for stopping was highly correlated to the regimen
received at the time of interruption (P = 0.0001). For example,
the reason for interrupting was adherence in only 5% of
patients taking 3 NRTIs (with abacavir) versus 46% of those
taking NNRTI-containing regimens, 60% of those taking
single PI regimens, and 38% of those taking ritonavir-boosted
PI regimens.
TABLE 1. General Baseline Characteristics of 3142 Patients of the I.Co.N.A. According to the Number and Duration of TIs
Characteristics at the Time of
Starting HAART
Continued HAART
or TI ,12 Weeks
(n = 2421)
One TI .12 Weeks
(n = 655)
Two or More TIs .12 Weeks
(n = 66) Total (n = 3142) P
Male, n (%) 1769 (73.1) 437 (66.7) 43 (65.2) 2249 (71.6) 0.003*
Age, years median (IQR) 36 (32–41) 35 (31–39) 35 (31–41) 36 (32–41) 0.0001†
Mode of transmission, n (%)
IDU 771 (31.9) 290 (44.3) 33 (50.0) 1094 (34.8) 0.0001*
Homo/bisexual 527 (21.8) 110 (16.8) 15 (22.7) 652 (20.8)
Heterosexual 940 (38.8) 225 (34.4) 16 (24.2) 1181 (37.6)
Other/unknown 183 (7.6) 30 (4.6) 2 (3.0) 215 (6.8)
Treatment history
Pretreated, n (%) 582 (24.0) 208 (31.8) 19 (28.8) 809 (25.8) 0.003*
CDC stage, n (%)
A 1527 (63.2) 465 (71.1) 41 (62.1) 2033 (64.9) 0.0001*
B 411 (17.0) 120 (18.4) 11 (16.7) 542 (17.3)
C 477 (19.8) 69 (10.6) 14 (21.2) 560 (17.9)
CD4 cells/mL
Median 267 359 320 284 0.0001†
IQR 112–428 195–555 149–495 127–450
HIV-RNA log10 copies/mL
Median 4.75 4.53 4.82 4.70 0.0001†
IQR 4.03–5.26 3.84–5.06 3.94–5.28 3.97–5.23
Calendar year of starting 0.0001*
1997 339 (14.0) 121 (18.5) 23 (34.9) 483 (34.9)
1998 586 (24.2) 226 (34.5) 19 (28.8) 831 (26.5)
1999 325 (13.4) 106 (16.2) 7 (10.6) 438 (13.9)
2000 456 (18.8) 117 (17.9) 11 (16.7) 584 (18.6)
2001 202 (8.3) 45 (6.9) 3 (4.6) 250 (8.0)
2002 262 (10.8) 30 (4.6) 3 (4.6) 295 (9.4)
2003–2004 251 (10.4) 10 (1.5) 0 (0.0) 261 (8.31)
HAART regimen, n (%)
2 NRTI + 1 PI 1400 (57.8) 422 (64.4) 48 (72.7) 1870 (59.5) 0.02*
2 NRTI + NNRTI 830 (34.3) 192 (29.3) 15 (22.7) 1037 (33.0)
2 NRTI + 2 PI 65 (2.7) 10 (1.5) 1 (1.5) 76 (2.4)
3 NRTI 106 (4.4) 22 (3.4) 2 (3.0) 130 (4.1)
Other 20 (0.8) 9 (1.4) 0 (0.0) 29 (0.9)
*x2 test.
†Kruskall-Wallis test.
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Factors Associated With the Probability
of First Interruption
When the absolute risk of interrupting therapy for the
first time was compared according to patients’ characteristics,
we found that interruptions were more frequently observed
among women (compared with men), injection drug users
(IDUs; compared with patients infected through other modes
of transmission), asymptomatic patients (vs. patients with a
previous diagnosis of AIDS), pretreated patients, patients with
a higher CD4 cell count nadir, and patients who initially started
HAART with a single PI-containing regimen (see Table 1).
The Kaplan-Meier estimate of the probability of
interrupting all drugs for at least 12 weeks for the first time
was 28.6% (95% CI: 26.7–30.6) by 4 years from HAART
initiation. In this univariate analysis, the rate of occurrence of
the first TI seemed to be high over the first 3 months (incidence
rate of 11.2 per 100 pys, 95% CI: 9.2–13.4); this rate remained
stable over the following 9 months but then almost halved after
the first year (5.9 per 100 pys, 95% CI: 5.3–6.5; RR compared
with 0–3months = 0.53, 95%CI: 0.43–0.65; P = 0.0001; Fig. 1).
From fitting a multivariate proportional hazards model,
women (vs. men [RH = 1.59, 95% CI: 1.15–2.19; P = 0.005]),
IDUs (vs. heterosexuals [RH = 1.73, 95% CI: 1.12–2.68; P =
0.01]), and patients with higher measurements of the most
recent CD4 count (CD4.350/mL [RH = 1.95, 95% CI: 1.25–
3.06] vs. CD4 #200/mL; P = 0.004) were more likely to
interrupt therapy for the first time for $12 weeks. In contrast,
as suggested by the Kaplan-Meier analysis and by analysis of
the incidence of interruptions over time, the adjusted RH of
interruption decreased in the 3- to 6-month follow-up period
(RH = 0.33, 95% CI: 0.21–0.52; P = 0.0001) and in the 6- to
9-month follow-up period (RH = 0.16, 95% CI: 0.11–0.24;
P = 0.0001) compared with the first 3 months.
In a subgroup analysis in which only the interruption
based on a patient’s decision was considered as an event (and
follow-up was censored at the date of interruption for other
reasons), in addition to the previous predictors, older patients
were less likely to interrupt (RH = 0.72, 95% CI: 0.54–0.96),
whereas antiretroviral-naive patients (vs. pretreated; RH =
1.52, 95% CI: 1.00–2.34; P = 0.05), patients coinfected with
hepatitis C virus (HCV; RH = 1.89, 95% CI: 1.08–3.28), and
patients with a higher pre-HAART viral load (RH = 1.42 per
log10 higher, 95% CI: 1.15–1.76; P = 0.001) were more likely
to stop.
Factors Associated With the Probability
of Restarting Therapy
Among the 721 patients who interrupted therapy, the
Kaplan-Meier estimate of the median time to resume therapy
after the time of the first TI was 12 months (95% CI: 11–14)
and 233 patients (32.3%) were still off therapy at the time of
their last clinical visit (censored).
From the Kaplan-Meier analysis using the minimum
CD4 cell count over follow-up as the ‘‘survival time’’ in the
subpopulation of patients who interrupted with a CD4 count
.200 cells/mL, by the time CD4 count had dropped to 200
cells/mL, 76.0% (95% CI: 70.4–81.3) of patients had resumed
therapy (Fig. 2). Consistently, when we compared the time to
therapy resumption using a multivariate proportional hazards
model, we found that the most recent CD4 count after
interruption was a strong predictor of the probability of
restarting therapy (RH = 0.92 per 100 cells/mL higher, 95%
CI: 0.89–0.96; P = 0.0001). Further, patients who stopped
because of failure (RH = 2.38 vs. those who stopped because
of their own decision, 95% CI: 1.56–3.63; P = 0.0001) and
those with a pre-HAART viral load higher than 100,000
copies/mL (RH = 1.79, 95% CI: 1.39–2.29 vs. pretherapy viral
load of 500–30,000 copies/mL; P = 0.0001) had a faster rate of
therapy resumption after interrupting for the first time. In
contrast, there was no evidence that the propensity to restart
therapy was different between patients interrupting because of
FIGURE 1. Kaplan-Meier curve: probability of first therapy
interruption in 3142 patients starting their first highly active
antiretroviral therapy regimen.
FIGURE 2. Probability of resuming therapy by current CD4
count in patients who had a CD4 count .200 cells/mL when
they interrupted highly active antiretroviral therapy. Each
individual contributed a single CD4 cell count to this analysis:
the minimum CD4 count observed during the follow-up
period.
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drug toxicity and those who stopped because of their own
decision (RH = 0.99, 95% CI: 0.78–1.26; P = 0.94).
Interruptions and Risk of Clinical Progression
Over the follow-up period, 281 (8.9%) of the 3142
patients studied experienced clinical progression (168 expe-
rienced a new AIDS-defining disease and 113 died). For 50%
of participants, the date of the clinical event occurred before
the date of their latest CD4 cell count; for an additional 25% of
participants, it was recorded within 2 months of their last
laboratory test. Overall, for only 5% of patients was the date of
the clinical event more than 8 months after the date at which
their CD4 count was last monitored. The Kaplan-Meier
estimate of the probability of clinical progression by 72
months from starting HAART was 12.9% (95% CI: 11.1–
14.5). Of the 168 AIDS-defining events, 21 (12.5%) were
Kaposi sarcoma, 17 (10.2%) were Mycobacterium tuberculo-
sis, 17 (10.2%) were esophageal candidiasis, 17 (10.2%) were
Mycobacterium avium infections, 15 (9.0%) were Pneumo-
cystis carinii pneumonia (PCP), 15 (9.0%) were non-Hodgkin
lymphoma, 13 (7.8%) were cytomegalovirus infections, 11
(6.6%) were HIV-related encephalopathy, 10 (6.0%) were
brain toxoplasmosis, 8 (4.8%) were recurrent pneumonia, 7
(4.2%) were progressive multifocal leukoencephalopathy, 6
(3.6%) were wasting syndrome, 5 (3.0%) were cervical cancer,
3 (1.8%) were cryptococcosis, 1 (0.6%) was primary brain
lymphoma, 1 (0.6%) was herpes simplex disease, and 1 (0.6%)
was isosporydiasis.
At the time of these events, 135 patients (48.0%) were
receiving prophylaxis against PCP or toxoplasmosis, 49
(17.4%) against mycobacteriosis, 15 (5.3%) against herpes
viruses, and 30 (10.7%) against fungal infections, and 8
(2.9%) were receiving other prophylactic drugs. Overall, only
57 patients (31.0%) were not receiving any prophylactic
treatment when they developed a clinical event.
In patients who experienced clinical progression, the
median CD4 count at the time of the events was 144 cells/mL
(IQR: 50–308 cells/mL) and the median HIV-RNA measure-
ment was 3.67 log10 copies/mL (IQR: 2.49–5.11 log10
copies/mL). A total of 245 patients (87.2%) had a clinical
event when they were receiving therapy (or were off therapy
for ,12 weeks) at a median CD4 count and viral load of 157
cells/mL (IQR: 59–329 cells/mL) and 3.18 log10 copies/mL
(IQR: 2.30–5.70 log10 copies/mL), respectively. Thirty-six
patients (12.8%) progressed to AIDS or death while they were
off therapy for at least 12 weeks, with a median CD4 count of
90 cells/mL (IQR: 18–178 cells/mL) and a median viral load of
4.94 log10 copies/mL (IQR: 3.92–5.35 log10 copies/mL). Thus,
in patients who were receiving therapy, clinical events
occurred at a significantly lower viral load (P = 0.0007) and
higher CD4 count (P = 0.002) than those observed in patients
who were off therapy.
The whole cohort represented 10,293 pys of follow-up,
which could be divided into 9251 pys on therapy or ,12
weeks off and 1042 pys of interruptions of at least 12 weeks.
Thus, the rate of clinical events while patients were on therapy
was 245 per 9251 pys (ie, 2.6 per 100 pys, Poisson exact 95%
CI: 2.3–3.0), and 36 events per 1042 pys were observed during
TI, giving a rate of 3.5 per 100 pys (95% CI: 2.4–4.8).
Therefore, the crude RR of AIDS and death during periods off
therapy compared with periods on therapy was 1.30 (95% CI:
0.89–1.86; P = 0.14).
In an attempt to evaluate the risk of clinical progression
associated with TI in a context in which CD4 counts during TI
were more closely monitored, we tested the hypothesis of the
presence of an interaction between the time-dependent
covariate indicating a TI and the current CD4 count (stratified
using the cutoffs of 50 and 200 cells/mL). The assumption was
that the strata with a current CD4 count of .200 cells/mL
would give an estimate of the risk of AIDS or death associated
with CD4 count–guided TI, during which it is unlikely to
observe a CD4 count #200 cells/mL. Indeed, this may
represent the only sensible way to distinguish between
different TIs in an observational setting. From this analysis
performed on the subset of patients with an available measure-
ment of the most recent CD4 count (281 events over 10,185
pys), there was little statistical evidence that the risk of clinical
progression associated with TI was different in patients with
different levels of current CD4 count (P = 0.41 for interaction).
At a high CD4 count, however, the absolute rates were more
similar between the 2 groups: the RH of AIDS or death
associated with a TI was 1.89 (95% CI: 1.05–3.36) in patients
with 0 to 50 cells/mL, the RH was 1.64 (95% CI: 0.98–2.73) in
those with 51 to 200 cells/mL, and the RH was 0.54 (95% CI:
0.24–1.21) in those with .200 cells/mL (Table 2).
Using a univariate Cox model and the time-dependent
covariate described in the section on methods, we found that
a TI of at least 12 weeks was associated with an RH of 3.45
compared with continued therapy (95% CI: 2.18–5.45; P =
0.0001). Having a TI of at least 12 weeks remained an
independent predictor of the risk of AIDS or death after
adjusting for baseline factors such as gender, age, mode of
HIV transmission, viral load, CD4 cell count, CDC disease
stage, and type of HAART regimen as well as the current
change in CD4 cell count and viral load from baseline (Table
3). Other factors independently associated with the risk of
AIDS or death from this analysis were the mode of HIV
transmission (IDUs were at higher risk than those infected via
heterosexual sex [RH = 1.85, 95% CI: 1.37–2.51; P = 0.0001])
at baseline CDC stage B vs. stage A ([RH = 1.47; 95% CI:
1.05–2.05, P = 0.03] or at stage C vs. stage A [RH = 2.23, 95%
CI: 1.63–3.06; P = 0.0001]) and a pretherapy viral load higher
than 100,000 copies/mL (RH = 1.47, 95% CI: 1.05–2.06)
versus a viral load 500 to 30,000 copies/mL (P = 0.03; see
Table 3). In contrast, patients with a higher CD4 count nadir
(CD4 count .350 cells/mL [RH = 0.38, 95% CI: 0.26–0.56;
P = 0.0001] and CD4 count of 201–350 cells/mL [RH = 0.60,
95% CI: 0.43–0.85; P = 0.004] both vs. CD4 count ,200
cells/mL) and with greater current viral load suppression on
therapy (.2 log10 copies/mL suppression less than pretherapy
levels [RH = 0.44, 95% CI: 0.23–0.83] vs.#1 log10 copies/mL
or increase; P = 0.01) were at a lower risk of clinical
progression (see Table 3).
Finally, from fitting a multivariate Cox model with
a time-dependent covariate capturing the duration of TI fitted
as a continuous variable rather than as a binary variable
indicating whether a patient was or was not off therapy for
longer than 12 weeks, the risk of clinical progression was
q 2005 Lippincott Williams & Wilkins 411
J Acquir Immune Defic Syndr  Volume 38, Number 4, April 1 2005 Interruption of HAART in HIV Clinical Practice
estimated to increase by 12% (95% CI: 1%–23%; P = 0.02)
per each additional month spent off therapy (see Table 3,
model 2).
DISCUSSION
Our analysis of a large cohort of patients, who were
mostly antiretroviral-naive before starting their first HAART
regimen, has shown that a substantial proportion of patients
are likely to experience a long TI (of at least 12 weeks), with
a probability of 28.6% by 4 years from the date of therapy
initiation; the median time of resuming therapy after this first
interruption was 12 months. Our analysis focused on
interruptions that occurred over the calendar period between
September 1997 and February 2004. Most regimens (46%)
that were interrupted were HAART combinations including
a single PI, that are no longer in use in the clinic. Nevertheless,
38% of the patients had an interrupted HAART combination
regimen containing an NNRTI or a ritonavir-boosted PI. It
would be interesting to repeat the analysis in the near future
when a higher percentage of patients would be receiving more
‘‘modern’’ combinations. The main reasons for stopping ther-
apy are related to patient requests and drug toxicities, account-
ing for 81% of the reasons reported by the treating physicians.
Patients receiving 3 NRTIs (with 1 being abacavir) were less
likely to interrupt because of nonadherence compared with the
other regimens.
Our analysis has shown that HAART interruption was
associated with a 3.5-fold increased risk of clinical progression
in a univariate Cox model. Because those who interrupted
therapy tended to have higher CD4 counts, however, this could
be an underestimate of the detrimental effect of TI. The CD4
count, being associated with the risk of clinical progression, is
a confounder (patients who interrupted tend to have a higher
CD4 count) and an intermediate variable (interruption affects
the CD4 count) in the association between TI and the risk of
developing AIDS or death, and standard Poisson or survival
analyses do not allow control of confounding without
simultaneous adjustment for the effect of TI on CD4 counts.
Approaches to estimation of relative risks in these circum-
stances have been suggested.25 We chose not to implement
these methods, because our focus was less on the exact
magnitude of the known negative effect of TI on clinical
progression and more on the effect of TI after adjustment for
the CD4 cell count and viral load. Indeed, even after adjust-
ment for the current CD4 cell count, viral load, and other
potential confounding factors, the RH remained significantly
raised at 2.75, suggesting that CD4 depletion (and the increase
in viral load) may only partly explain the increased risk in
clinical progression during TI.
Treatment interruptions are commonly observed in
clinical settings, and a large proportion of patients who
decide to interrupt therapy are known to physicians, who,
although are not encouraging this policy, may have no
convincing arguments to discourage it; thus, a critical evalua-
tion of this phenomenon as well as of its impact on the clinical
course of HIV infection is needed. Specifically, it is unclear
whether the potential risks of interrupting therapy can be
compensated for by its potential benefits, for example, in terms
of reduction of exposure to antiretroviral drugs and potential
TABLE 2. Incidence of Clinical Events in Periods When Patients Were On or Off
Therapy According to the Current CD4 Count (Only 10,185 pys With a Measure of
CD4 Count Were Used)
Current
CD4 Count
Off
Therapy
On
Therapy Total Crude RR (95% CI) P
.200
Events 6 100 106
pys 883 7917 8800
Rate 100 pys 0.6 1.3 1.2
(95% CI) (0.2–1.5) (1.0–1.5) (0.9–1.5) 0.53 (0.24–1.21) P = 0.14
51–200
Events 17 87 104
pys 125 1021 1146
Rate 100 pys 13.7 8.5 0.9
(95% CI) (7.9–21.8) (6.8–10.5) (0.7–1.1) 1.64 (0.98–2.73) P = 0.06
0–50
Events 13 58 71
pys 26 215 241
Rate 100 pys 50.0 26.9 29.4
(95% CI) (26.6–85.5) (20.5–35.9) (23.0–37.2) 1.89 (1.06–3.36) P = 0.03
Total
Events 36 245 281
pys 1033 9152 10,185
Rate 100 pys 3.2 2.7 2.8
(95% CI) (2.2–4.5) (2.4–3.0) (2.4–3.1)
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TABLE 3. Factors Independently Associated With the Probability of Developing New AIDS Related Events or Death
From Fitting a Proportional Hazards Model
Crude Analysis Adjusted Analysis
Factor Crude RH (95% CI) P Adjusted RH (95% CI) P
Men 1.00 1.00
Women 0.69 (0.52–0.91) 0.01 0.84 (0.61–1.16) 0.29
Age, years
Per 10 years older 1.14 (0.99–1.29) 0.06 1.05 (0.90–1.23) 0.51
Mode of HIV transmission
Heterosexual 1.00 1.00
IDU 1.79 (1.35–2.36) 0.0001 1.85 (1.37–2.51) 0.0001
Homo/bisexual 1.20 (0.8–1.69) 0.32 1.21 (0.83–1.77) 0.33
Other/unknown 1.23 (0.73–2.08) 0.43 1.13 (0.66–1.92) 0.65
TI
Model 1
No or ,12 weeks 1.00 1.00
Yes 3.45 (2.18–5.45) 0.0001 2.75 (1.14–6.65) 0.03
Model 2
Per month longer 1.03 (1.01–1.05) 0.0007 1.12 (1.01–1.23) 0.02
1993 CDC classification
A 1.00 1.00
B 2.03 (1.48–2.80) 0.0001 1.47 (1.05–2.05) 0.03
C 4.04 (3.11–5.26) 0.0001 2.23 (1.63–3.06) 0.0001
CD4 count nadir
Model 1
Per 100 cells/mL higher 0.70 (0.65–0.75) 0.0001 0.80 (0.74–0.87) 0.0001
Model 2 (categoric)
0–200 1.00 1.00
201–350 0.40 (0.30–0.55) 0.0001 0.60 (0.43–0.85) 0.004
.350 0.21 (0.15–0.29) 0.0001 0.38 (0.26–0.56) 0.0001
Current CD4 count change from baseline
Model 1
Per 100 cells/mL greater 0.84 (0.73–0.97) 0.01 0.96 (0.83–1.11) 0.58
Model 2 (categoric)
#100 or decrease 1.00 1.00
101–200 increase 0.59 (0.30–1.15) 0.12 0.72 (0.34–1.52) 0.39
.200 increase 0.66 (0.38–1.14) 0.14 1.04 (0.56–1.95) 0.90
Pretherapy viral load
Model 1
Per log10 copies/mL higher 1.59 (1.39–1.88) 0.0001 1.21 (1.04–1.40) 0.01
Model 2 (categoric)
501–30,000 1.00 1.00
30,001–100,000 1.62 (1.14–2.31) 0.007 1.30 (0.90–1.86) 0.16
.100,000 2.45 (1.80–3.37) 0.0001 1.47 (1.05–2.06) 0.03
Current viral load suppression relative to baseline
Model 1
per log10 copies/mL greater 0.71 (0.60–0.85) 0.0002 0.76 (0.63–0.92) 0.004
Model 2 (categoric)
#1 log or increase 1.00 1.00
1–2 logs suppression 0.60 (0.30–1.20) 0.15 0.63 (0.31–1.31) 0.29
.2 logs suppression 0.41 (0.23–0.72) 0.002 0.44 (0.23–0.83) 0.01
Adjusted RHs for covariates other than CD4 count and viral load (fitted as categoric) are from fitting model 1.
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improvements of toxicity profiles and quality of life. Indeed,
treatment ‘‘holidays’’ can potentially reduce the stress of
continuous timing of the drugs,26 probability of experiencing
side effects and toxicities such as dyslipidemia, and modifi-
cations of the body shape or lipodystrophy known to be related
to prolonged use of therapy.27
In contrast, the benefits associated with an enhancement
of the HIV-specific cellular immune response after a TI seem
to be negligible. Data from pilot studies and randomized trials
on supervised TI in chronically infected patients with well-
controlled viral replication showed a partial restoration of HIV-
specific cellular immunity after TI but also little evidence that
this immune response was then capable of controlling viral
replication.9–11
To our knowledge, there are few published data on TIs
and their consequences in clinical settings, and the results are
conflicting. An important study, including a large number of
patients enrolled in the Swiss cohort, considered TI up to only
3 months.17 In that study of 4720 patients, 1299 of whom
underwent TI, the authors did not find any correlations
between interruption of therapy and death or new AIDS-
defining events. In contrast, in a randomized study of a group
of 270 patients with multidrug-resistant HIVand a plasma viral
load .5000 copies/mL, a 4-month STI was associated with
greater progression of disease without immunologic or virol-
ogic benefits or improvement of quality of life.14
We decided to address the problem in another way by
considering only presumably preplanned interruptions with
a duration of 3 months or more, because this is becoming
a relatively common situation in clinical settings, and to look
at the possible detrimental effect of such interruptions on
clinical progression of HIV infection. Most of these interrup-
tions were made on the basis of patient decision. Unfortu-
nately, the reason for interruption in our database is collected
using the general classification of ‘‘patient decision,’’ and the
real reason why patients are making such a decision is not
specified; however, we can speculate that a consistent
proportion of interruptions is decided on between patients
and treating clinicians and is a result of side effects or other
clinical reasons.
The first observation from our data is that the likelihood
of interrupting treatment (for at least 3 months) decreased with
longer exposure to therapy. Because more than half of the
interruptions seemed to be determined by patient decision and
another 24% by drug toxicity, it could be argued that the
commitment of our patients to therapy is not so strong and, in
turn, that long-term toxicities do not yet have a large impact on
this cohort. This may be explained by the fact that most of our
patients were antiretroviral naive at enrollment; consequently,
the total time of exposure to HAART is relatively shorter
compared with that of patients in other cohorts. Actually, only
24 patients interrupted therapy because of lipodystrophy, and
16 interrupted therapy because of metabolic toxicities (data
not shown).
Women, IDUs, and, if the decision for interrupting was
primarily made by the patient, HCV antibody–positive
individuals were more likely to interrupt therapy; another
previous analysis has shown that women and HCV-coinfected
subjects of the I.Co.N.A. are at higher risk of experiencing
toxicities.7,28 Moreover, TIs seemed more likely to occur at
higher values of the current CD4 cell count, further confirming
that most interruptions are in the context of successful rather
than failing therapy. From our estimates, patients with a current
CD4 count higher than 350 cells/mL are almost twice as likely
to interrupt therapy as those with a current CD4 count ranging
between 201 and 350 cells/mL.
It is important to observe that the median time to therapy
resumption was 1 year. Given a median decay of 16 CD4
cells/mL per month, as reported in 72 patients interrupting
a successful therapy regimen for more than 12 weeks,29 over
a time span of 1 year, the risk of experiencing critical CD4
count levels is high. In our cohort, even if the decision to
interrupt therapy was mainly made by the patients, it was
possible to monitor their level of immunosuppression during
the periods when they were off therapy. Actually, the decision
to resume therapy seemed to be mainly driven by the CD4 cell
count during interruption, and more than 75% of patients
interrupting therapy with CD4 counts greater than 200
cells/mL resumed therapy once the CD4 count dropped to
less than 200 cells/mL. The probability of resuming therapy
was 8% lower per 100 cells/mL higher in the most recent CD4
count; in addition, patients stopping therapy because of failure
were 2.4 times more likely to resume it than those interrupting
based on their own decision. Similar results have been
obtained in other cohort studies.30
Most importantly, our data have shown a detrimental
effect of therapy interruptions of more than 12 weeks on the
short-term risk of clinical progression. These results are
consistent with those of a previous cohort study.21 Moreover,
subjects who already have AIDS and those with a higher viral
load before starting therapy were also at higher risk of clinical
progression, whereas those with a higher CD4 count nadir
were at lower risk; these findings confirm the established
importance of baseline CD4 counts and HIV-RNA copy levels
in predicting the clinical outcome of HAART.31,32 Interest-
ingly, the risk of AIDS or death was also reduced in patients
with current viral suppression from pretherapy levels of .2
log10 copies/mL compared with those with a reduction less than
1 log10.
In conclusion, TIs of at least 12 weeks are not uncom-
mon in clinical practice; in up to 80% of our cases, they were
requested by the patients or seemed to be associated with
drug-related toxicity. Women, IDUs, and HCV-infected indi-
viduals seemed to be at a higher risk of having interruptions.
Once therapy is interrupted for 12 weeks or more, patients
seem to remain off therapy, on average, for 1 year, and the
decision to restart therapy is mainly based on CD4 cell count
depletion. Unfortunately, the risk of clinical progression
during these interruptions seems to be remarkably higher than
that of patients under continuous therapy such that patients
interrupting treatment need to be accurately monitored and
perhaps discouraged outside strictly experimental settings.
When the current CD4 count was .200 cells/mL, there was
some evidence that the risk of AIDS or death in patients
who had interrupted therapy and in those remaining on
HAART was similarly low, suggesting that more analyses
should be carried out in patients with this level of CD4 cell
count.
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APPENDIX
The I.Co.N.A. study group consists of the following
individuals:
Italy
Ancona: M. Montroni, G. Scalise, A. Zoli, M. S. Del
Prete; Aviano (PN): U. Tirelli, G. Di Gennaro; Bari: G. Pastore,
N. Ladisa, G. Minafra; Bergamo: F. Suter, C. Arici; Bologna:
F. Chiodo, V. Colangeli, C. Fiorini, O. Coronado; Brescia:
G. Carosi, G. P. Cadeo, F. Castelli, C. Minardi, D. Vangi; Busto
Arsizio: G. Rizzardini, G. Migliorino; Cagliari: P. E. Manconi,
P. Piano; Catanzaro: T. Ferraro, A. Scerbo; Chieti:
E. Pizzigallo, M. D’Alessandro; Como: D. Santoro,
L. Pusterla; Cremona: G. Carnevale, D. Galloni; Cuggiono:
P. Vigano`, M. Mena; Ferrara: F. Ghinelli, L. Sighinolfi;
Firenze: F. Leoncini, F. Mazzotta, M. Pozzi, S. Lo Caputo;
Foggia: G. Angarano, B. Grisorio, S. Ferrara; Galatina (LE):
P. Grima, P. Tundo; Genova: G. Pagano, N. Piersantelli,
A. Alessandrini, R. Piscopo; Grosseto: M. Toti, S. Chigiotti;
Latina: F. Soscia, L. Tacconi; Lecco: A. Orani, P. Perini; Lucca:
A. Scasso, A. Vincenti; Macerata: F. Chiodera, P. Castelli;
Mantova: A. Scalzini, G. Fibbia; Milano: M. Moroni,
A. Lazzarin, A. Cargnel, G. M. Vigevani, L. Caggese,
A. d’Arminio Monforte, D. Repetto, R. Novati, A. Galli,
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S. Merli, C. Pastecchia, M. C. Moioli; Modena: R. Esposito,
C. Mussini; Napoli: N. Abrescia, A. Chirianni, C. Izzo,
M. Piazza, M. De Marco, V. Montesarchio, E. Manzillo,
M. Graf; Palermo: A. Colomba, V. Abbadessa, T. Prestileo,
S. Mancuso; Parma: C. Ferrari, P. Pizzaferri; Pavia: G. Filice,
L. Minoli, R. Bruno, S. Novati; Perugia: F. Balzelli, K. Loso;
Pesaro:E.Petrelli,A.Cioppi; Piacenza: F.Alberici;A.Ruggieri;
Pisa: F.Menichetti, C.Martinelli; Potenza: C. De Stefano,A. La
Gala; Ravenna: G. Ballardini, E. Briganti; Reggio Emilia:
G. Magnani, M. A. Ursitti; Rimini: M. Arlotti, P. Ortolani;
Roma: R. Cauda, F. Dianzani, G. Ippolito, A. Antinori,
G. Antonucci, S. D’Elia, P. Narciso, N. Petrosillo, V. Vullo,
A. De Luca, A. Del Forno, M. Zaccarelli, R. Acinapura, P. De
Longis, M. Ciardi, G. D’Offizi, M. P. Trotta, P. Noto,
M. Lichtner, M. R. Capobianchi, E. Girardi, P. Pezzotti,
G. Rezza; Sassari: M. S. Mura, M. Mannazzu; Torino:
P. Caramello, A. Sinicco, M. L. Soranzo, L. Gennero,
M. Sciandra, M. Bonasso; Varese: P. A. Grossi, C. Basilico;
Verbania: A. Poggio, G. Bottari; Venezia: E. Raise,
S. Pasquinucci; Vicenza: F. De Lalla, G. Tositti; Taranto:
F. Resta, A. Chimienti
United Kingdom
London: A. Cozzi Lepri
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